Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.